# Clinical Trials Data KIT - Document 63

# Effectiveness of Microwave Ablation of Hepatocellular Carcinoma as Compared to Radiofrequency Ablation

## Clinical Trial: https://clinicaltrials.gov/study/NCT01340105

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Age \\>18 years\n\* Unresectable hepatocellular carcinoma (HCC) and tumor amendable for local ablation\n\* Resectable HCC but patient opts for local ablation\n\* Maximum diameter of tumor \u22646cm\n\* Maximum number of tumor nodules \u22643\n\* Absence of radiology evidence of major vascular or bile duct invasion\n\* Child's A or B liver function\n\* Karnofsky performance status \u226570%\n\nExclusion Criteria:\n\n\* Informed consent not available\n\* Pregnant female patients\n\* Tumors unfavourable for local ablation (e.g. tumor close to porta hepatis)\n\* HCC with history of rupture\n\* Concomitant hepatectomy\n\* Patients with chronic renal failure",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a KIT gene mutation be eligible for the clinical trial?

Answer:  
This trial is specifically for hepatocellular carcinoma (HCC). The provided information says nothing about KIT gene mutations, either as an inclusion or exclusion criterion. Therefore, having a KIT gene mutation \*doesn't automatically disqualify\* a patient. They would need to meet all other inclusion criteria and not meet any exclusion criteria to be eligible.